AlloyX Group Announces Collaboration with Bricopia Inc. to Develop World’s First Biological Asset-Backed Security (BABS)

Hong Kong, SAR, Jan.27, 2026 – AlloyX Group (Nasdaq: AXG), a global leader of digital finance infrastructure, announced today that the company has entered a strategic collaboration with Bricopia, Inc. (“Bricopia”), a leading U.S. based life science company, to jointly launch the world’s first biological asset-backed security (BABS) based on the tokenization of the real-world assets (RWA), representing a new approach to structuring life science assets.

Tokenization of real-world assets has gained increasing institutional attention in recent years. This collaboration aims to transform Bricopia's high-value biological assets into regulatory-compliant and traceable digital securities through blockchain technology.

As the technology and compliance partner for this collaboration, AXG will leverage its deep expertise in asset tokenization and digital securitization to provide Bricopia with an end-to-end fintech solution.

Dr. Thomas Zhu, Co-founder and CEO of AlloyX Group, stated: “AXG is committed to innovations in fintech infrastructure and the practical RWA applications. We recognize that assets in the life sciences sector, such as high-value biological patents and research and development achievements, have long faced challenges related to illiquidity and difficulty in valuation. Through our in-depth collaboration with Bricopia, we are not only engaging in technological integration but also exploring a new category of digitally securitized assets—the tokenization of biological assets. Leveraging our regulatory-compliant advantages in Hong Kong and global markets, we will promote the cross-sector integration of financial technology and life sciences, opening up a transparent and efficient new path for asset allocation for global investors.”

Bricopia's core technology, including a series of patented automated cell processing and manufacturing systems approved by the U.S. Food and Drug Administration (FDA), addresses the three most critical challenges in the industry: (1) anti-tampering, (2) one-to-one mapping, and (3) third-party auditability.

Harvey Tien, Board Director at Bricopia, stated: “Bricopia owns the industry-leading automated cell banking technologies and is building a global network of biological assets. Through a strategic partnership with AlloyX Group, we are able to leverage blockchain technology to transform these illiquid biological assets into more liquid digital assets, separating asset ownership from liquidity, potentially unlocking significant market opportunities.”

This collaboration between AXG and Bricopia is not only a technological breakthrough, but also a new approach to traditional life science business models. The new business model addresses the challenges of the highly segmented healthcare industry and provides exit strategies for business owners and investors. In the future, investors will be able to participate in this high-barrier healthcare sector through regulatory-compliant digital assets, sharing the achievements of global research and developments.

About AlloyX Group:

AlloyX Group (Nasdaq: AXG) is a global integrated financial services institution bridging traditional finance and digital assets ecosystem. The Group operates across stablecoin payments, tokenization service, digital brokerage, and on-chain financial infrastructure. By integrating traditional brokerage and banking systems with blockchain technology, AlloyX Group delivers secure, efficient, and auditable digital financial solutions for institutions. Backed by leading international investors, we are building the next generation digital financial infrastructure empowering the global transition toward a regulated digital economy.

About Bricopia Inc:

Bricopia Inc. is an innovative biotechnology company based in California, USA, specializing in biotechnology, blockchain, and AI technology. The company's core business is focused on the development, commercialization and marketing of a range of automated technologies for cell banking, CAR-T and other cell-based therapies.